Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC)

The Journal of Liquid Biopsy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles